{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:23:25Z","timestamp":1793363005662,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antibody-mediated rejection (ABMR) is a major cause of chronic allograft dysfunction and graft loss after kidney transplantation (KTx). Daratumumab, antibody targeting the transmembrane glycoprotein CD38 (cluster of differentiation) on immune cells, has shown promise in the treatment of refractory ABMR in adult solid organ transplantation; however, pediatric data are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report two pediatric cases of refractory ABMR after KTx treated with daratumumab with followed-up protocol biopsies over 10\u201312 months. Treatment consisted of an induction phase with five weekly doses followed by maintenance dosing every two to four weeks. Donor-specific antibodies (DSAs), kidney function, albuminuria, and histologic response were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The first case, a 10-year-old girl with recurrent ABMR after KTx showed histologic improvement from active ABMR with C4d positivity, glomerulitis, and severe microvascular inflammation to predominantly chronic changes without signs of active rejection. Microvascular inflammation became mild and C4d staining turned negative. The second case, a 9-year-old boy with active and chronic antiglomerular basement membrane disease and severe transplant ABMR glomerulopathy initially showed progression of chronic injury, followed by complete histologic resolution of active disease, disappearance of C4d staining, minimal fibrosis (&amp;lt;1%), and marked reduction of albuminuria after 10 months. Both patients demonstrated reduced DSA levels, stabilization of graft function, and no serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Daratumumab was associated with histologic improvement, reduction of microvascular inflammation, and stabilization of graft function in two children with refractory ABMR after KTx. Controlled studies to determine the safety, efficacy, and optimal dosage of daratumumab in children with ABMR are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag236","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:27:05Z","timestamp":1783942025000},"source":"Crossref","is-referenced-by-count":1,"title":["Treatment response to daratumumab in antibody-mediated kidney allograft rejection: evidence from serial protocol biopsies"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-4906","authenticated-orcid":false,"given":"Nele Kirsten","family":"Kanzelmeyer","sequence":"first","affiliation":[{"name":"Department of Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Verboom","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallensleben","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bade-D\u00f6ding","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sch\u00f6n","sequence":"additional","affiliation":[{"name":"Department of Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9601-7813","authenticated-orcid":false,"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[{"name":"Department of Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Hinrich","family":"Br\u00e4sen","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-6318","authenticated-orcid":false,"given":"Anette","family":"Melk","sequence":"additional","affiliation":[{"name":"Department of Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"2026080421112107900_bib1","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibodymediatedrejection after kidney transplantation: the 2019 expert consensus from the Transplantation Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"2026080421112107900_bib2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.kint.2021.11.029","article-title":"Allorecognition and the spectrum of kidney transplant rejection","volume":"101","author":"Callemeyn","year":"2022","journal-title":"Kidney Int"},{"key":"2026080421112107900_bib3","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.ajt.2025.03.031","article-title":"Microvascular inflammation in kidney allografts: new directions for patient management","volume":"25","author":"B\u00f6hmig","year":"2025","journal-title":"Am J Transplant"},{"key":"2026080421112107900_bib4","doi-asserted-by":"publisher","first-page":"e70116","DOI":"10.1111\/petr.70116","article-title":"Daratumumab for treatment of acute antibody-mediated rejection in a pediatric kidney transplant recipient","volume":"29","author":"Connolly","year":"2025","journal-title":"Pediatr Transplant"},{"key":"2026080421112107900_bib5","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026080421112107900_bib6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection","volume":"105","author":"Doberer","year":"2021","journal-title":"Transplantation"},{"key":"2026080421112107900_bib7","doi-asserted-by":"publisher","first-page":"1087597","DOI":"10.3389\/fimmu.2022.1087597","article-title":"Case report: daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies","volume":"13","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"2026080421112107900_bib8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000503951","article-title":"Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation","volume":"9","author":"Spica","year":"2019","journal-title":"Case Rep Nephrol Dial"},{"key":"2026080421112107900_bib9","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1016\/j.ekir.2025.07.009","article-title":"Anti-CD38 daratumumab treatment of chronic active antibody-mediated kidney allograft rejection","volume":"10","author":"Lye","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026080421112107900_bib10","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.ajt.2023.06.018","article-title":"Daratumumab for antibody-mediated rejection: is it time to target the real culprit?","volume":"23","author":"de\u00a0Nattes","year":"2023","journal-title":"Am J Transplant"},{"key":"2026080421112107900_bib11","first-page":"11","article-title":"Blood group-specific apheresis in combination with daratumumab as a rescue therapy of acute antibody-mediated rejection in a case of ABO- and human leukocyte antigen-incompatible kidney transplantation","volume":"7","author":"S\u00fcsal","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"2026080421112107900_bib12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40620-024-02182-5","article-title":"Searching for the minimum required dose of daratumumab to induce effective plasma cell depletion in antibody-mediated rejection of the kidney graft: a case report","volume":"38","author":"Oll\u00e9","year":"2025","journal-title":"J Nephrol"},{"key":"2026080421112107900_bib13","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/jha2.936","article-title":"Successful treatment of refractory donor-specific-human leukocyte antigen-antibody-induced primary graft-failure with daratumumab: a case report","volume":"5","author":"Lesan","year":"2024","journal-title":"EJHaem"},{"key":"2026080421112107900_bib14","doi-asserted-by":"publisher","first-page":"e70106","DOI":"10.1111\/petr.70106","article-title":"Daratumumab for anti-HLA antibody desensitization and antibody mediated rejection in pediatric heart transplant patients","volume":"29","author":"Milligan","year":"2025","journal-title":"Pediatr Transplant"},{"key":"2026080421112107900_bib15","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.healun.2022.06.017","article-title":"Daratumumab provides transient response of antibody mediated rejection post pediatric orthotopic heart transplantation","volume":"41","author":"Fenton","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"2026080421112107900_bib16","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/TP.0000000000003505","article-title":"Daratumumab for antibody-mediated rejection in heart transplant-a novel therapy: successful treatment of antibody-mediated rejection","volume":"105","author":"Aguilera\u00a0Agudo","year":"2021","journal-title":"Transplantation"},{"key":"2026080421112107900_bib17","doi-asserted-by":"publisher","first-page":"100386","DOI":"10.1016\/j.jhlto.2025.100386","article-title":"CD38-targeted therapy with daratumumab in clinical lung transplantation: a single-center experience","volume":"10","author":"Hillebrand","year":"2025","journal-title":"JHLT Open"},{"key":"2026080421112107900_bib18","doi-asserted-by":"publisher","first-page":"e15458","DOI":"10.1111\/tan.15458","article-title":"Daratumumab treatment in six highly sensitised solid organ transplant recipients: a case series and literature review","volume":"103","author":"Lemal","year":"2024","journal-title":"HLA"},{"key":"2026080421112107900_bib19","doi-asserted-by":"publisher","first-page":"13213","DOI":"10.3389\/ti.2024.13213","article-title":"Donor-derived cell-free DNA as a companion biomarker for ABMR treatment with daratumumab: case series","volume":"37","author":"Osmanodja","year":"2024","journal-title":"Transpl Int"},{"key":"2026080421112107900_bib20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12882-025-03951-5","article-title":"Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study","volume":"26","author":"Guo","year":"2025","journal-title":"BMC Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag236\/70021479\/sfag236.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/8\/sfag236\/70021479\/sfag236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/8\/sfag236\/70021479\/sfag236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:11:31Z","timestamp":1785892291000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag236\/8741819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag236","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,25]]},"article-number":"sfag236"}}